BioCircuit Technologies
Private Company
Total funding raised: $26.2M
Overview
BioCircuit Technologies is a commercial-stage medical device company that has successfully launched Nerve Tape®, a novel sutureless nerve repair device. The product demonstrates significant advantages over traditional microsuture, including being 4.8x faster and 2.6x stronger, and has seen rapid adoption with over 3,500 implants within 16 months of launch. The company is expanding its portfolio with products like the ConformaWrap® Nerve Protector and is positioned for growth in the large peripheral nerve repair and neuromodulation markets.
Technology Platform
Biomaterial-based micro-mechanical platform for sutureless nerve connection, featuring flexible strips with integrated microscale hooks that attach to the nerve sheath to distribute tension and enable rapid repair.
Funding History
10Opportunities
Risk Factors
Competitive Landscape
The primary competition is the entrenched standard of care: manual microsuturing. Other competitors may include existing nerve conduits and wraps, but none offer the same sutureless coaptation mechanism. BioCircuit's first-mover advantage with Nerve Tape® provides a temporary monopoly in its specific niche, but it may face future competition from novel glue-based or other sutureless technologies.